Calls for papers
-
Teva’s Qnaze beclomethasone nasal aerosol has met all efficacy endpoints in a Phase III trial. The study involved 470 patients with perennial allergic rhinitis. After 6 weeks of treatment, patients using the product experienced significant… Read more . . .
-
Pharmaxis has received TGA approval to market its Bronchitol inhaled dry powder mannitol in Australia for the treatment of cystic fibrosis. The approval is for patients over 6 years old. Bronchitol received orphan drug designation… Read more . . .
-
According to Teva, its worldwide sales of respiratory drugs, including the Pro-Air albuterol and QVAR beclomethasone inhalers, were down 3% from 2009, to $875 million. Of that amount, $556 million is attributable to sales in… Read more . . .
-
Isis Pharmaceuticals has reportedly closed down Altair Therapeutics, which it had spun off in 2007 to develop AIR645, an inhaled IL-4 and IL-13 inhibitor for the treatment of asthma. The drug, which was the only… Read more . . .
-
An article in the January 31, 2011 issue of PNAS describes how rhesus macaques gained protection against the measles virus after inhalation of a single dose of a dry powder live attenuated measles vaccine (LAMV).… Read more . . .
-
AstraZeneca has announced that it has received marketing authorization from the European Commission for its Fluenz nasal spray vaccine for the prevention of seasonal flu in children under 18 years old down to 24 months… Read more . . .
-
A severe winter storm has necessitated postponement of Gateway Analytical’s grand opening ceremony from February 1 to April 12. Gateway is a subsidiary of ChemImage and offers particle analysis services including ingredient-specific particle sizing for… Read more . . .
-
Assuming that MAP Pharmaceuticals’ Levadex inhaled dihydroergotamine for the treatment of migraine receives FDA approval, Allergan will market the product to pain specialists and neurologists in the US. MAP will handle marketing to primary care… Read more . . .
-
According to BASF, its new Ultraform N2320 003 PRO plastic for injection molding is specifically designed for medical applications with highly-stressed components, including dry powder inhalers. The new plastic will become commercially available in February… Read more . . .
-
California-based biotech company Ligand Pharmaceuticals has acquired CyDex Pharmaceuticals and its Captisol solubility-enhancing technology. CyDex’s pipeline includes a Captisol-enhanced budesonide/azelastine nasal spray. Ligand will operate CyDex as a wholly-owned subsidiary. Read the company’s press release. Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland